Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its audited results for the year ended 31 December 2025.  The Group reported revenue growth of 7% (6% in constant currency) to $3.349 billion, compared to $3.127 billion in 2024 with growth in all three geographies, North America, MENA, and Europe.  Said Darwazah, […] The post Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes appeared first on Web-Release.